Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer

Journal:

The New England Journal of Medicine

Published:

2025-06-01

DOI:

10.1056/nejmoa2505725

Affiliations:

28

Authors:

27

Go to article

Institutions	Authors	Share
Pfizer Italia srl, Italy	2.000000	0.07
Arvinas, United States of America (USA)	2.000000	0.07
Institute of Cancer Research (ICO), France	2.000000	0.07
IRCCS Istituto Nazionale Tumori IRCCS-Fondazione G. Pascale, Italy	1.000000	0.04
Sant'Orsola Malpighi Hospital, Italy	1.000000	0.04
Memorial Ankara Hospital, Turkey	1.000000	0.04
Pfizer, United States of America (USA)	1.000000	0.04
Fundación Respirar, Argentina	1.000000	0.04
Beijing Hospital, China	1.000000	0.04
Centre Jean Perrin (CJP), France	1.000000	0.04
University Hospital of Pisa, UNIPI, Italy	1.000000	0.04
Centre Georges-François Leclerc (CGFL), France	1.000000	0.04
Hospital General Universitario de Elche, Spain	1.000000	0.04
The University of Osaka (UOsaka), Japan	1.000000	0.04
Başkent University, Turkey	1.000000	0.04
Grand River Hospital, Canada	1.000000	0.04
Sunnybrook Health Sciences Centre, U of T, Canada	1.000000	0.04
Sarah Cannon Research Institute (SCRI), United States of America (USA)	1.000000	0.04
Fudan University Shanghai Cancer Center (FUSCC), China	1.000000	0.04
The First Hospital of Jilin University, China	1.000000	0.04
San Gerardo Hospital, Italy	1.000000	0.04
University of Padova (UNIPD), Italy	0.500000	0.02
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)	0.500000	0.02
Weill Cornell Medicine, United States of America (USA)	0.500000	0.02
IRCCS Istituto Oncologico Veneto (IOV), Italy	0.500000	0.02
Adana City Training and Research Hospital, Turkey	0.500000	0.02
University of Health Sciences (SBU), Turkey	0.500000	0.02

Interested in Organic Chemistry?